TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01969838
Drug: Placebo to match momelotinib
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match momelotinib tablets administered orally once daily
Study: NCT01969838
Drug: Placebo to match ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match ruxolitinib tablets administered orally twice daily
Study: NCT02855294
Drug: COC containing 30 μg of EE and 3mg of drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
Study: NCT01933334
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
Study: NCT00094380
Drug: CTLA4-IgG4m (RG2077)
Normalized name: Anti-ctla4 mab (biocad)
DrugBank: Nurulimab (DB18946)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00226941
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
Study: NCT00226941
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
Study: NCT00226941
Drug: Diphenhydramine hydrochloride (HCl)
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
Study: NCT00541047
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00541047
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00541047
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04840095
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplement is administered mid-scan.
Study: NCT00014144
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002526
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00889421
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral dose of 30 mg BID for 6 months
Study: NCT04499157
Drug: MEMOPTIC
Normalized name: Timoptic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
Study: NCT04499157
Drug: usual treatment of glaucoma
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive only their usual treatment of glaucoma.
Study: NCT00486343
Drug: Zileuton CR
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton CR tablets 2x600mg BID for 24 weeks
Study: NCT01392352
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 x 400mg pazopanib tablets taken once daily for 12 weeks
Study: NCT00003945
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003945
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02265705
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT04611997
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
Study: NCT01946061
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
Study: NCT01229436
Drug: Xiapex
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
Study: NCT01141296
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fenofibrate 200 mg PO daily for 1 year
Study: NCT00781326
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
Study: NCT00003326
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02344186
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Crossover design - 24 weeks on active drug and 12 weeks daily placebo
Study: NCT00491790
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 4 mg rapid dissolving granules in sterile water given orally once
Study: NCT02073968
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02073968
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00638547
Drug: IRT Laronidase
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture
Study: NCT01180075
Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.
Study: NCT01180075
Drug: tenofovir/emtricitabine (TDF/FTC)
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.
Study: NCT01180075
Drug: Atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
Study: NCT01180075
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
Study: NCT00881725
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
Study: NCT00793910
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 300 mg taken by mouth thrice daily for 7 days
Study: NCT02308202
Drug: doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02308202
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01168934
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
Study: NCT01168934
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
Study: NCT03686774
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery.
Study: NCT01491243
Drug: Intensive treatment with sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
Study: NCT00187798
Drug: Metformin HCl
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
Study: NCT01525082
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide by mouth daily on Days 10 to 14
Study: NCT01032941
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
Study: NCT02925975
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
Study: NCT00005638
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005638
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01778192
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
Study: NCT01778192
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
Study: NCT01778192
Drug: Sodium picosulphate with magnesium citrate
Normalized name: Primatene with ephedrine Pill
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
Study: NCT01778192
Drug: Sodium picosulphate with magnesium citrate
Normalized name: Primatene with ephedrine Pill
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
Study: NCT01702233
Drug: Fortecortin/Dexamethasone 8 mg/2 ml inj
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
Study: NCT04266977
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: restrictive use of DEX, based on standardized clinical and radiological criteria.
Study: NCT02056301
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
Study: NCT02056301
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
Study: NCT04584567
Drug: Doxycyclin
Normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily (100mg)
Study: NCT00004317
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm descriptions
Study: NCT00004317
Drug: Spiramycin
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Spiramycin is administered before the fetal diagnosis is made.
Study: NCT00004317
Drug: Sulfadiazine
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm descriptions
Study: NCT01809626
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02985736
Drug: Topicort Topical Spray
Normalized name: desoximetasone Topical Spray [Topicort]
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00374777
Drug: zolpidem MR
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00374777
Drug: nitrazepam
Normalized name: nitrazepam
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01390246
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg tablet
Study: NCT01266759
Drug: NuvaRing
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
Study: NCT01266759
Drug: Norethisterone Acetate tablets - 5mg
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
Study: NCT04034589
Drug: Pyrotinib combined with fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
Study: NCT02669186
Drug: Bupivacaine + Fentanyl
Normalized name: Fentanyl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
Study: NCT02669186
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
Study: NCT03971643
Drug: vilobelimab
Normalized name: Vilobelimab
DrugBank: Vilobelimab (DB16416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of vilobelimab diluted in sodium chloride.
Study: NCT01485952
Drug: SEN0014196 (Low Dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg once daily administration (immediate release capsule)
Study: NCT01485952
Drug: SEN0014196 (High Dose)
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once daily administration (immediate release capsule)
Study: NCT00078390
Drug: S-3304
Normalized name: S-3304
DrugBank: S-3304 (DB12149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
Study: NCT00582582
Drug: Docetaxel plus doxercalciferol
Normalized name: Doxercalciferol
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
Study: NCT00582582
Drug: Docetaxel plus placebo
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
Study: NCT02279641
Drug: allopurinol 300 mg
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02510157
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: active comparator
Study: NCT02510157
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
Study: NCT00930358
Drug: MEOPA
Normalized name: homeopathic drugs
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anaesthetic gaz inhalation
Study: NCT02422030
Drug: Trilipix 135mg
Normalized name: Trilipix 135mg Delayed-Release Capsule
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095184
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg daily
Study: NCT02095184
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg daily
Study: NCT03639480
Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Normalized name: amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Study: NCT03639480
Drug: Amlodipine 10mg+Valsartan 160mg
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amlodipine 10mg+Valsartan 160mg
Study: NCT03639480
Drug: Valsartan 160mg+Atorvastatin 40mg
Normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160mg+Atorvastatin 40mg
Study: NCT00003335
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
Study: NCT00003335
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine begin on day -2 and continue for 6 months.
Study: NCT00003335
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan IV for three days on days -4 to -2
Study: NCT00003335
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
Study: NCT00718718
Drug: CNTO 136 100 mg
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
Study: NCT00718718
Drug: CNTO 136 50 mg
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
Study: NCT00718718
Drug: CNTO 136 25 mg
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
Study: NCT02358824
Drug: CKD-828
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)